- Home
- TRVI vs AUTL Comparison
TRVI vs AUTL Comparison
Compare TRVI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- AUTL
- Stock Information
- Founded
- TRVI 2011
- AUTL 2014
- Country
- TRVI United States
- AUTL United Kingdom
- Employees
- TRVI N/A
- AUTL N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRVI Health Care
- AUTL Health Care
- Exchange
- TRVI Nasdaq
- AUTL Nasdaq
- Market Cap
- TRVI 629.8M
- AUTL 625.4M
- IPO Year
- TRVI 2019
- AUTL 2018
- Fundamental
- Price
- TRVI $5.96
- AUTL $2.05
- Analyst Decision
- TRVI Strong Buy
- AUTL Strong Buy
- Analyst Count
- TRVI 8
- AUTL 5
- Target Price
- TRVI $19.31
- AUTL $9.32
- AVG Volume (30 Days)
- TRVI 2.5M
- AUTL 2.3M
- Earning Date
- TRVI 08-07-2025
- AUTL 08-07-2025
- Dividend Yield
- TRVI N/A
- AUTL N/A
- EPS Growth
- TRVI N/A
- AUTL N/A
- EPS
- TRVI N/A
- AUTL N/A
- Revenue
- TRVI N/A
- AUTL $9,011,000.00
- Revenue This Year
- TRVI N/A
- AUTL $461.76
- Revenue Next Year
- TRVI N/A
- AUTL $112.66
- P/E Ratio
- TRVI N/A
- AUTL N/A
- Revenue Growth
- TRVI N/A
- AUTL N/A
- 52 Week Low
- TRVI $2.36
- AUTL $1.11
- 52 Week High
- TRVI $7.48
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- TRVI 43.31
- AUTL 59.29
- Support Level
- TRVI $6.05
- AUTL $1.98
- Resistance Level
- TRVI $6.49
- AUTL $2.10
- Average True Range (ATR)
- TRVI 0.53
- AUTL 0.15
- MACD
- TRVI -0.05
- AUTL -0.03
- Stochastic Oscillator
- TRVI 27.62
- AUTL 44.53
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.